DOCSLIB.ORG

Abstract Section

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Technologist Presentations A Note on 2018 Technologist Abstracts For the Technologist Abstract track, 35 scientifi c papers have been accepted for presentation at the 65th SNMMI Annual Meeting at the Philadelphia Convention Center, Philadelphia, PA. The Program Committee for the SNMMI Technologist Section (SNMMI-TS) will be hosting 5 oral sessions to present these scientifi c papers, to be held on Sunday, June 24, and Monday, June 25; refer to the 2018 Annual Meeting Program Book for specifi c times and locations. Each oral session is 90 minutes in duration and includes up to seven 12-minute presentations per session. For the Technologist Abstract track, 70 scientifi c posters have been accepted for presentation. The SNMMI-TS Program Committee will be hosting a Technologist “Meet the Author” poster session, scheduled for Monday, June 25, from 3:00PM-4:30PM. The posters will be on display and available for viewing by attendees in the Poster Hall (Exhibit Hall C). SNMMI Abstracts Online: Accepted abstracts for the 65th SNMMI Annual Meeting are citable and searchable by visiting the JNM website at: http://jnm.snmjournals.org/ SUNDAY SESSIONS value of this promising approach. Interesting innovation arise from the application of fl uorinated PSMA-ligands yielding F18-specifi c advantages compared to Ga68 (e.g. longer Half-life, lower positron range, higher Tech Papers I: Clinical PET production of activity). Authors listed for this abstract reported no relevant fi nancial disclosures. Moderator: Mary Beth Farrell, MS, CNMT, NCT, FSNMMITS Co-Moderator: April Mann 2102 The evaluation of the spatial resolution of 11C-, 18F- and 64Cu-PET 2101 Technologists Track images on a clinical PET/CT scanner using Monte Carlo Simulation and phantom examination. Saki Kimoto1, Naoki Hashimoto1, Ayano Ga68PSMA PET/MRI a revolution to detect primary prostate cancer. Shoji1, Yuji Tsutsui1,2, Kazuhiko Himuro2, Shingo Baba, MD, PhD2, Sylvia Schachoff1, Tobias Maurer2, Stephan G. Nekolla1, Markus Akihiko Takahashi1, Masayuki Sasaki, MD, PhD3; 1Kyushu University, Schwaiger, MD1, Wolfgang A. Weber, MD1, Matthias Eiber, MD1; Fukuoka, Japan, 2Kyushu University Hospital, Fukuoka, Japan, 3Dept Rad 1Nuclear Medicine, TU Munich, Munich, Germany, 2Department of Sci Sch of Health Sci Kyushu Univ, Fukuoka, Japan. (1762) Urology, Munich, Germany. (2095) Purpose: The goal of this study was to evaluate the spatial resolution of Aim: Defi ne a PET/MR study protocol using Ga68-PSMA for patients PET images on PET/CT scanner using 11C (0.960 MeV), 18F (0.633 MeV) with elevated PSA value and negative prostate biopsies but high suspicion and 64Cu (0.650 MeV) by Monte Carlo Simulation (MCS) and phantom of tumor. examination. Methods: For patients with suspected primary prostate cancer, Ga68- Materials and Methods: In MCS, spherical sources (diameter: 0.7 mm) PSMA-PET MRI is a novel and promising imaging technique. Ga68- of 11C, 18F and 64Cu were generated and 10, 000 annihilation positions of PSMA is a new PET tracer that targets the active center of the extracellular positrons were recorded. The full width at half maximum (FWHM) and the domain of PSMA - a protein with high expression in prostate cancer but full width at tenth maximum (FWTM) were measured from the distribution low anywhere else in the body. In our clinical routine 45 % of Ga68-PSMA function of the positron annihilation positions, and the FWHM to FWTM PET/MR examinations are for primary prostate cancer with half of them ratio (FWHM/FWTM) was then calculated. In the phantom examination, in patient with increased PSA and prior negative prostate biopsies. Our the PET data were acquired using a Biograph mCT scanner. The point PET/MRI protocol combines the advantages of molecular information from sources (inner diameter: 0.7 mm) with 11C, 18F and 64Cu were placed at PET with a state of the art multi-parametric MRI of the prostate (T2w 3D, transaxial positions (0, 1) cm. The radioactivity concentration was 21.2 diffusion, dynamic contrast-enhanced sequence). The examination takes MBq/mL. The data were acquired in the three-dimensional list mode and about 35 minutes and requires an optimal preparation of the patients (e.g. then were reconstructed using fi ltered back projection. A Gaussian fi lter MRI contraindications, laboratory values such as PSA and creatinine). was not used. The image matrix was 400×400 and the slice thickness was Results: Ga68-PSMA PET imaging allows direct visualization of PSMA- 5 mm. The FWHM, the FWTM and the FWHM/FWTM were calculated avid tumor lesions independent of metabolism - thus regenerative and from the PET images. infl ammatory change have hardly any infl uence). The soft-tissue contrast Results: On MCS, the FWHM/FWTM of 11C, 18F and 64Cu were 0.284, of MRI-sequences and their anatomical resolution in combination with 0.396 and 0.396, respectively. 11C, which has the highest positron energy, the PET-signal, clearly help to diagnose prostate cancers, especially in the showed the smallest FWHM/FWTM. On the phantom examination, the transition zone which is diffi cult for MRI alone. The information of our FWHM/FWTM of 11C, 18F and 64Cu were 0.439±0.03, 0.423±0.03 and Ga68-PSMA PET/MR dataset is used in by local urologists to perform 0.444±0.04, respectively. There were no signifi cant differences among the PET-MRI-Ultrasound-Fusion guided biopsies. This helps to increase cancer FWHM/FWTM of 11C, 18F and 64Cu. detection rate in a diffi cult patient population. Conclusions: In conclusion, the positron energy was considered to Summary: Ga68-PSMA PET/MR is a novel method to detect prostate infl uence the theoretical spatial resolution of positron imaging in MCS, but cancer in men with prior negative biopsies but persistently elevated PSA- no such infl uence was observed on the clinical PET images. Therefore, the values. Combining PET with MRI using PET/MRI rather than PET/CT spatial resolution of clinical PET images seems to be too low to measure allows integral assessment of functional and molecular information and differences in positron energy among 11C, 18F and 64Cu. provide soft-tissue contrast to enable imaging guided biopsy. Based on our experience additional investigations are necessary to defi ne the exact Authors listed for this abstract reported no relevant fi nancial disclosures. 2018 TECHNOLOGIST SECTION ABSTRACTS 155 Technologists Track 2103 of CRP and ESR. Plasma PTX3 levels were also measured by enzyme- linked immunosorbent assay (ELISA) in all of the above patients. We have Evaluation of metabolic tumor volume using different image 1 introduced a new indicator named Ratio.V(Ratio.V = artery/liver * volum reconstruction algorithm on 18F-FDG PET image. Seok Hwan Yoon , of the lesion) as a quantitative indicator which considering the volum of Hong Jae Lee1, Gyeong Woon Noh1, Jae Sung Lee, PhD2, Jin Chul Paeng, 1 1 1 lesion measured in ture D mode. The Ratio(artery/liver) >1.0 was set as the MD, PhD , Keon Wook Kang, MD, PhD , Dong Soo Lee, MD, PhD , gold standard to determine the activity of arteritis, according to the previous June-Key Chung, MD, PhD1; 1Seoul National University Hospital, Seoul, 2 clinical studies. Korea, Republic of, Seoul National University, Seoul, Korea, Republic Results: 34 patients in TKA group were determined to be active by 18F- of. (1562) FDG PET/CT. The level of plasma PTX-3 in active TKA patients was signifi cantly higher than that in non-active TKA patients (3.56±0.54 v.s. Purpose: Recently, MTV(Metabolic tumor volume) has been used 1.15±0.09, p<0.05). PTX3 level was positively correlated with the Ratio.V as indices of the whole tumor FDG uptake on FDG PET image. but it (Spearman r=0.59,p<0.001). No signifi cant correlation were found between is infl uenced by image reconstruction. The purpose of this study was to the Ratio.V and the level of CRP or ESR (Spearman r=0.37 and 0.23, p evaluate the correlation of MTV applied different SUVmax threshold for =0.04 and 0.21). Under the guidance of 18F-FDG PET/CT, the specifi city different reconstruction algorithm on phantom and patient study. of PTX-3 diagnosis was 79.41% and the sensitivity was 87.10%, and the Methods: In phantom study, Measurement were performed on a area under the receiver operating characteristic curve (AUC) was 0.88. This Siemens Biograph mCT40 PET/CT using a NEMA IEC body phantom result is signifi cantly better than the results of CRP (76.47%,67.74%,0.72) containing different size six spheres fi lled with F18-FDG by applying or ESR(79.41%,58.06%,0.72). four signal to background ratios (4:1, 8:1, 10:1, 20:1). MTV of images Conclusion: The serum level of PTX3 was signifi cantly correlated with reconstructed four algorithms (OSEM3D, OSEM3D+PSF, OSEM3D+TOF, the infl ammatory activity of TKA detected by 18F-FDG PET/CT and its OSEM3D+PSF+TOF) were measured with different SUVmax threshold. quantitative relevance was much better than CRP or ESR. The diagnostic (30%, 35%, 40%, 45%, 50%, 55%, 60%). In patient study, we compared effi cacy especially sensitivity was also superior to that of CRP and ESR. MTV of tumor by applying different threshold of SUVmax in FDG PET PTX3 may better refl ect the severity of TKA and may be a potential images of 52 patients with lung cancer. To evaluate statistical analysis, biological marker to monitor the disease status of TKA. Wilcoxon test, Concordance correlation coeffi cient and Kruskal-Wallis test were performed. Authors listed for this abstract reported no relevant fi nancial disclosures. Results: In phantom, Overall, the use of increasing SUVmax threshold result in decreasing MTV.
Recommended publications
  • UC Irvine UC Irvine Previously Published Works

    UC Irvine UC Irvine Previously Published Works

    UC Irvine UC Irvine Previously Published Works Title Astrophysics in 2006 Permalink https://escholarship.org/uc/item/5760h9v8 Journal Space Science Reviews, 132(1) ISSN 0038-6308 Authors Trimble, V Aschwanden, MJ Hansen, CJ Publication Date 2007-09-01 DOI 10.1007/s11214-007-9224-0 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Space Sci Rev (2007) 132: 1–182 DOI 10.1007/s11214-007-9224-0 Astrophysics in 2006 Virginia Trimble · Markus J. Aschwanden · Carl J. Hansen Received: 11 May 2007 / Accepted: 24 May 2007 / Published online: 23 October 2007 © Springer Science+Business Media B.V. 2007 Abstract The fastest pulsar and the slowest nova; the oldest galaxies and the youngest stars; the weirdest life forms and the commonest dwarfs; the highest energy particles and the lowest energy photons. These were some of the extremes of Astrophysics 2006. We attempt also to bring you updates on things of which there is currently only one (habitable planets, the Sun, and the Universe) and others of which there are always many, like meteors and molecules, black holes and binaries. Keywords Cosmology: general · Galaxies: general · ISM: general · Stars: general · Sun: general · Planets and satellites: general · Astrobiology · Star clusters · Binary stars · Clusters of galaxies · Gamma-ray bursts · Milky Way · Earth · Active galaxies · Supernovae 1 Introduction Astrophysics in 2006 modifies a long tradition by moving to a new journal, which you hold in your (real or virtual) hands. The fifteen previous articles in the series are referenced oc- casionally as Ap91 to Ap05 below and appeared in volumes 104–118 of Publications of V.
  • Brain Imaging

    Brain Imaging

    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
  • March 21–25, 2016

    March 21–25, 2016

    FORTY-SEVENTH LUNAR AND PLANETARY SCIENCE CONFERENCE PROGRAM OF TECHNICAL SESSIONS MARCH 21–25, 2016 The Woodlands Waterway Marriott Hotel and Convention Center The Woodlands, Texas INSTITUTIONAL SUPPORT Universities Space Research Association Lunar and Planetary Institute National Aeronautics and Space Administration CONFERENCE CO-CHAIRS Stephen Mackwell, Lunar and Planetary Institute Eileen Stansbery, NASA Johnson Space Center PROGRAM COMMITTEE CHAIRS David Draper, NASA Johnson Space Center Walter Kiefer, Lunar and Planetary Institute PROGRAM COMMITTEE P. Doug Archer, NASA Johnson Space Center Nicolas LeCorvec, Lunar and Planetary Institute Katherine Bermingham, University of Maryland Yo Matsubara, Smithsonian Institute Janice Bishop, SETI and NASA Ames Research Center Francis McCubbin, NASA Johnson Space Center Jeremy Boyce, University of California, Los Angeles Andrew Needham, Carnegie Institution of Washington Lisa Danielson, NASA Johnson Space Center Lan-Anh Nguyen, NASA Johnson Space Center Deepak Dhingra, University of Idaho Paul Niles, NASA Johnson Space Center Stephen Elardo, Carnegie Institution of Washington Dorothy Oehler, NASA Johnson Space Center Marc Fries, NASA Johnson Space Center D. Alex Patthoff, Jet Propulsion Laboratory Cyrena Goodrich, Lunar and Planetary Institute Elizabeth Rampe, Aerodyne Industries, Jacobs JETS at John Gruener, NASA Johnson Space Center NASA Johnson Space Center Justin Hagerty, U.S. Geological Survey Carol Raymond, Jet Propulsion Laboratory Lindsay Hays, Jet Propulsion Laboratory Paul Schenk,
  • Digitalcommons@UTEP

    Digitalcommons@UTEP

    University of Texas at El Paso DigitalCommons@UTEP Open Access Theses & Dissertations 2017-01-01 Her Alessandra Narvaez-Varela University of Texas at El Paso, [email protected] Follow this and additional works at: https://digitalcommons.utep.edu/open_etd Part of the Creative Writing Commons, and the Women's Studies Commons Recommended Citation Narvaez-Varela, Alessandra, "Her" (2017). Open Access Theses & Dissertations. 509. https://digitalcommons.utep.edu/open_etd/509 This is brought to you for free and open access by DigitalCommons@UTEP. It has been accepted for inclusion in Open Access Theses & Dissertations by an authorized administrator of DigitalCommons@UTEP. For more information, please contact [email protected]. HER ALESSANDRA NARVÁEZ-VARELA Master's Program in Creative Writing APPROVED: Sasha Pimentel, Chair Andrea Cote-Botero, Ph.D. David Ruiter, Ph.D. Charles Ambler, Ph.D. Dean of the Graduate School . Copyright © by Alessandra Narváez-Varela 2017 For my mother—Amanda Socorro Varela Aragón— the original Her HER by ALESSANDRA NARVÁEZ-VARELA, B.S in Biology, B.A. in Creative Writing THESIS Presented to the Faculty of the Graduate School of The University of Texas at El Paso in Partial Fulfillment of the Requirements for the Degree of MASTER OF FINE ARTS Department of Creative Writing THE UNIVERSITY OF TEXAS AT EL PASO December 2017 Acknowledgements Thank you to the editors of Duende for publishing a previous version of “The Cosmic Millimeter,” and to the Department of Hispanic Studies at the University of Houston for the forthcoming publication of a chapbook featuring the following poems: “Curves,” “Savage Nerd Cunt,” “Beauty,” “Bride,” “An Education,” “Daddy, Look at Me,” and “Cut.” Thank you to Casa Cultural de las Américas for sponsoring the reading that made this chapbook possible.
  • Action Figures

    Action Figures

    Action Figures Star Wars (Kenner) (1977-1983) Power of the Force Complete Figures Imperial Dignitary Masters of the Universe (1982-1988) Wave 1 Complete Figures Battle Ram (Vehicle) Castle Grayskull (Playset) Accessories Man-At-Arms - Mini-comic (The Vengeance of Skeletor), Mace, Leg Armor Zodac - Mini-comic (The Vengeance of Skeletor or Slave City!) Beast Man - Whip, Spiked Arm Band, Spiked Arm Band Mer-Man - Mini-comic Teela - Snake Staff Wave 2 Accessories Trap Jaw - Mini-comic (The Menace of Trap Jaw!), Hook Arm, Rifle Arm Wave 3 Complete Figures Battle Armor He-Man Mekaneck (figure and accessories detailed below) Accessories Battle Armor Skeletor - Ram Staff Webstor - Grapple Hook with string Fisto - Sword Orko - Mini-comic (Slave City!), Magic Trick Whiplash - Mini-comic (The Secret Liquid of Life) Weapons Pack - Yellow Beast Man Chest Armor, Yellow Beast Man Arm Band, Gray Grayskull Shield, Gray Grayskull Sword Mekaneck - Club, Armor Wave 4 Complete Figures Dragon Blaster Skeletor (figure and accessories detailed below) Moss Man (figure and accessories detailed below) Battle Bones (Creature) Land Shark (Vehicle) Accessories Dragon Blaster Skeletor - Sword, Chest Armor, Chain, Padlock Hordak - Mini-comic (The Ruthless Leader's Revenge) Modulok - 1 Tail, Left Claw Leg Moss Man - Brown Mace Roboto - Mini-comic (The Battle for Roboto) Spikor - Mini-comic (Spikor Strikes) Fright Zone - Tree, Puppet, Door Thunder Punch He-Man - Shield Wave 5 Complete Figures Flying Fists He-Man Horde Trooper (figure and accessories detailed below) Snout
  • NEURACEQ Safely and Effectively

    NEURACEQ Safely and Effectively

    HIGHLIGHTS OF PRESCRIBING INFORMATION • Obtain 15-20 minute PET images starting from 45 to 130 minutes after These highlights do not include all the information needed to use intravenous administration (2.3) NEURACEQ safely and effectively. See full prescribing information for • Image interpretation: refer to full prescribing information (2.4) NEURACEQ. • The radiation absorbed dose from a 300 MBq (8.1 mCi) dose of Neuraceq is 5.8 mSv in an adult (2.5). NEURACEQ (florbetaben F 18 injection), for intravenous use Initial U.S. Approval: 2014 --------------------- DOSAGE FORMS AND STRENGTHS -------------------­ 30 mL multi-dose vials containing a clear injectable solution at a strength of --------------------------- INDICATIONS AND USAGE -------------------------- 50 to 5000 MBq/mL (1.4 to135 mCi/mL) florbetaben F18 at End Of Synthesis Neuraceq™ is a radioactive diagnostic agent indicated for Positron Emission (EOS). At time of administration 300 MBq (8.1 mCi) are contained in up to Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque 10 mL solution for injection (3) density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A ------------------------------ CONTRAINDICATIONS ----------------------------­ negative Neuraceq scan indicates sparse to no neuritic plaques and is None (4) inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s ----------------------- WARNINGS AND PRECAUTIONS ---------------------­ cognitive impairment is due to AD. A positive Neuraceq scan indicates • Image interpretation errors (especially false positives) have been observed moderate to frequent amyloid neuritic plaques; neuropathological examination (5.1).
  • Northern Ireland Nuclear Medicine Equipment Survey, 2017

    Northern Ireland Nuclear Medicine Equipment Survey, 2017

    Northern Ireland nuclear medicine equipment survey 2017 Northern Ireland nuclear medicine equipment survey 2017 About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support. Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland © Crown copyright 2019 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned. Published January 2019 PHE publications PHE supports the UN Sustainable Development Goals 2 Northern Ireland nuclear medicine equipment survey 2017 Contents Executive summary 4 Introduction 5 Methodology 6 Number of procedures performed 7 Procedures per scanner 8 Age of Scanners 9 Procedures reported for each organ or system 10 Procedures reported
  • October 2019 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs

    October 2019 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs

    WWW.SNMMI.ORG Final Rule 2020 Compared to October 2019 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs October 2019 Rates CY 2020 Final Rule Updated April 2, 2020 Status Item/Code/Service OPPS Payment Status Indicator Services furnished to a hospital outpatient that are paid under a fee schedule or Not paid under OPPS. Paid by MACs under a fee schedule or payment system other than OPPS. payment system other than OPPS,* for example: A ● Separately Payable Clinical Diagnostic Laboratory Services (Not subject to Services are subject to deductible or coinsurance unless indicated otherwise. deductible or coinsurance.) D Discontinued Codes Not paid under OPPS or any other Medicare payment system. Items and Services: ● Not covered by any Medicare outpatient benefit category Not paid by Medicare when submitted on outpatient claims (any outpatient bill E1 ● Statutorily excluded by Medicare type). ● Not reasonable and necessary Items and Services: Not paid by Medicare when submitted on outpatient claims (any outpatient bill ● for which pricing information and claims data are not E2 type). available G Pass-Through Drug/ Biologicals Paid under OPPS; separate APC payment NonPass-Through Drugs and nonimplantable Biologicals, including Therapeutic Paid under OPPS; separate APC payment K Radiopharmaceuticals Paid under OPPS; payment is packaged into payment for other services. Items and Services packaged into APC rate N Therefore, there is no separate APC payment. Paid under OPPS; Addendum B displays APC assignments when services are separately payable. (1) Packaged APC payment if billed on the same claim as a HCPCS code STV-Packaged assigned status indicator “S,” “T,” or “V.” Q1 Codes (2) Composite APC payment if billed with specific combinations of services based on OPPS composite-specific payment criteria.
  • Mechanisms of Radiopharmaceutical Localization

    Mechanisms of Radiopharmaceutical Localization

    .::VOLUME 16, LESSON 4::. Mechanisms of Radiopharmaceutical Localization Continuing Education for Nuclear Pharmacists And Nuclear Medicine Professionals By James A. Ponto, MS, RPh, BCNP Chief Nuclear Pharmacists, University of Iowa Hospitals and Clinics and Professor (Clinical), University of Iowa Hospitals and Clinics The University of New Mexico Health Sciences Center, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program No. 0039-000-12-164- H04-P 2.5 Contact Hours or .25 CEUs. Initial release date: 7/19/2012 -- Intentionally left blank -- Mechanisms of Radiopharmaceutical Localization By James A. Ponto, MS, RPh, BCNP Editor, CENP Jeffrey Norenberg, MS, PharmD, BCNP, FASHP, FAPhA UNM College of Pharmacy Editorial Board Stephen Dragotakes, RPh, BCNP, FAPhA Michael Mosley, RPh, BCNP Neil Petry, RPh, MS, BCNP, FAPhA James Ponto, MS, RPh, BCNP, FAPhA Tim Quinton, PharmD, BCNP, FAPhA S. Duann Vanderslice, RPh, BCNP, FAPhA John Yuen, PharmD, BCNP Advisory Board Dave Engstrom, PharmD, BCNP Vivian Loveless, PharmD, BCNP, FAPhA Brigette Nelson, MS, PharmD, BCNP Brantley Strickland, BCNP Susan Lardner, BCNP Christine Brown, BCNP Director, CENP Administrator, CE & Web Publisher Kristina Wittstrom, MS, RPh, BCNP, FAPhA Christina Muñoz, M.A. UNM College of Pharmacy UNM College of Pharmacy While the advice and information in this publication are believed to be true and accurate at the time of press, the author(s), editors, or the publisher cannot accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, expressed or implied, with respect to the material contained herein.
  • A Message from the Director-General

    A Message from the Director-General

    A message from the Director-General I am very glad to be able to contribute this introduction to the first CERN COURIER of 1962. We have been without our journal for quite a long time, but we can now look forward to seeing it regularly again once a month. CERN COURIER is an important publication of ours, because not only does it serve to link together all members of the Organization, and their families, but it also has a strong part to play in showing CERN to the member States and to other parts of the world. This institution is remarkable in two ways: It is a place where the most fantastic experiments are carried out. It is a place where international co-operation actually exists. These two statements call for some explanation: It is difficult to appreciate the full significance of an activity if all one's energy is devoted to it. The everyday work accomplished at CERN Message from the Director- hides its real importance, the tremendous impact of what is going on General 2 here. What I am tempted to call the 'romantic glory' of our work is over­ looked. But you must never forget that in the PS, at the moment when Last year at CERN 3 the beam hits a target, at the moment when matter undergoes a transfer Radiation safety at CERN . 4 of energy, you have created conditions which probably do not exist Johan Baarli 8 anywhere else in the universe, not even in the explosions of super-nova stars. What an opportunity to penetrate the innermost structure of matter CERN theoretical conference .
  • FDG PET for the Diagnosis of Dementia

    FDG PET for the Diagnosis of Dementia

    PET for Clinicians Christopher C. Rowe MD FRACP Austin Health University of Melbourne PET in dementia is not new but only in recent years, as PET has become more accessible, has a clinical role emerged. Austin Health, Melbourne does 1000 brain PET per year. Parieto-temporal hypometabolism in AD Clinical Diagnosis of AD • Sensitivity 80%, Specificity 70% (Knopfman, Neurology 2001- average of 13 studies with pathological confirmation) i.e. diagnosis requires dementia and only has moderate accuracy Mild Cognitive Impairment (MCI) does not equate to early AD • Only 50% of MCI will progress to AD dementia • 15-20% have other dementias. • 35-40% do not develop dementia. We need biomarkers for early diagnosis of AD and other dementias! New Research Criteria for AD (2007)* • dementia or significant functional impairment is NOT required • clear history of progressive cognitive decline • objective evidence from psychometric tests of episodic memory impairment • characteristic abnormalities in the CSF or in neuroimaging studies (MRI, FDG-PET, Aβ PET) *Dubois B, Feldman HH, Jacova C, et al. Lancet 2007. FDG PET in Alzheimer’s disease Parietotemporal hypometabolism Reiman EM et al. New Engl J Med 1996;334(12):752–758. View in AC-PC plane bottom of frontal lobe and occipital lobe on same horizontal plane in mid sagittal image Prefrontal Primary sensori-motor cortex Parietal Austin & Repatriation Medical Centre Department of Nuclear Medicine & Centre for PET Reading Brain PET Compare: • parietal vs sensori-motor and frontal • posterior cingulate vs
  • SNMMI Fact Sheet Amyloid.Indd

    SNMMI Fact Sheet Amyloid.Indd

    Amyloid PET Imaging INDICATION: • Amyloid imaging radiopharmaceuticals are indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. RADIOPHARMACEUTICALS (FDA APPROVED): • 18F-Florbetapir (Amyvid™, Eli Lilly) • 18F-Florbetaben (NeuraCeq™, Piramal Life Sciences) • 18F-Flutemetamol (Vizamyl™, GE Healthcare) CONTRAINDICATIONS: • Inability to cooperate with PET brain imaging. • Amyloid PET imaging should be performed on a pregnant woman only if there is a clear clinical benefi t. • Previous reaction to the radiopharmaceutical or any excipient. ADVERSE REACTIONS (SEE INDIVIDUAL PACKAGE INSERT FOR COMPLETE LISTINGS): • 18-F Florbetapir (Amyvid™) - headache (<2%), dizziness, nausea (<1%), fatigue (<1%), injection site reaction (<1%). • 18F-Florbetaben (NeuraCeq™) - injection site reactions (<2%) consisting of erythema, irritation and pain. • 18F-Flutemetamol (Vizamyl™) - fl ushing (2%), blood pressure increase (2%), headache (1%), nausea (1%), dizziness (1%) STORAGE: • Store radiopharmaceutical at room temperature. • Radiopharmaceutical is provided in unit dose syringe and must not be diluted. PATIENT PREPARATION: • It is not necessary for patients to be NPO prior to imaging. • It is not necessary to control the post injection conditions (e.g. ambient light, temperature, noise). • It is not necessary to discontinue any medications. • Patient should wear comfortable clothing, with no metal on head (hair clips, earrings, etc.) • If patient is breast feeding, recommend discontinuation of breast feeding for 24 hours after administration of radiopharmaceutical. • It is often useful to engage a family member or caregiver in the process of explaining the scan procedure and assessing the patient’s ability to follow instructions.